- Home
- RGA vs BMRN Comparison
RGA vs BMRN Comparison
Compare RGA & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGA | BMRN |
|---|---|---|
| Founded | 1973 | 1996 |
| Country | United States | United States |
| Employees | 4300 | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 10.4B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | RGA | BMRN |
|---|---|---|
| Price | $207.50 | $55.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 18 |
| Target Price | ★ $241.50 | $88.22 |
| AVG Volume (30 Days) | 296.0K | ★ 2.3M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $11.38 | $15.02 |
| Revenue Next Year | $6.11 | $12.23 |
| P/E Ratio | ★ $12.58 | $104.02 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $165.52 | $49.26 |
| 52 Week High | $229.21 | $66.28 |
Technical Indicators
Market Signals| Indicator | RGA | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 53.34 |
| Support Level | $203.05 | $51.74 |
| Resistance Level | $209.08 | $56.91 |
| Average True Range (ATR) | 4.04 | 1.74 |
| MACD | 0.25 | 0.35 |
| Stochastic Oscillator | 59.86 | 58.45 |
Price Performance
Historical ComparisonAbout RGA Reinsurance Group of America Incorporated
Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.